Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Keytruda Clears MHLW Panel for Both 1st-Line, 2nd-Line NSCLC
A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) on November 24 backed approval for MSD’s immune checkpoint inhibitor Keytruda (pembrolizumab) for the treatment of PD-L1-positive unresectable, advanced or relapsed non-small cell lung cancer (NSCLC) both…
To read the full story
Related Article
- MHLW OKs Tecfidera, Otezla, Other Drugs
December 20, 2016
- Keytruda Gets NSCLC Nod Both in 1st-Line, 2nd-Line Settings
December 20, 2016
- MHLW Panel OKs Celgene’s Apremilast, 2 Other NMEs
November 25, 2016
REGULATORY
- MHLW Taps Kawabata to Lead Drug Discovery Support Office
April 15, 2026
- MHLW Reviewing EMIS Data on Petro-Product Supply to Medical Institutions
April 15, 2026
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
- LDP, Ishin to Explore Role of Private Insurance in Reform Talks
April 14, 2026
- Middle East War Hitting API Air Freight, Trade Group Warns
April 13, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…